Multiple Myeloma | Specialty

Clinical Data for Selinexor Use in Myeloma

June 11th 2021

Experts in treating multiple myeloma discuss the trials that led to the approval of selinexor with bortezomib and dexamethasone, and which patient population would benefit from treatment, as well as the dosing, safety, and efficacy.

Cilta-cel Yields Survival Benefit vs Standard Treatment in Triple–Relapsed/Refractory Multiple Myeloma

June 11th 2021

Ciltacabtagene autoleucel demonstrated efficacious responses and significant improvements in survival over standard of care in triple class–relapsed/refractory multiple myeloma.

CAR T-Cell Therapy-Associated Toxicities Could Be Mitigated With Anakinra Prophylaxis in Multiple Myeloma

June 11th 2021

The incidence of grade ≥2 cytokine release syndrome was lower in patients with relapsed or refractory multiple myeloma who received anakinra prophylaxis with orvacabtagene autoleucel, a B-cell maturation antigen-targeted CAR T-cell therapy.

Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong

June 9th 2021

OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.

Subcutaneous Elranatamab Elicits Encouraging Responses in Relapsed/Refractory Myeloma

June 8th 2021

The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.

Talquetamab at RP2D Elicits High Clinical Response Rate in Relapsed/Refractory Multiple Myeloma

June 8th 2021

Talquetamab, when delivered at the recommended phase 2 dose of 405 µg/kg weekly, induced a high clinical response rate with favorable tolerabilty in patients with relapsed/refractory multiple myeloma.

Teclistamab Demonstrates Encouraging Efficacy, Safety at the RP2D in Relapsed/Refractory Multiple Myeloma

June 8th 2021

Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.

Cilta-Cel Demonstrates Durable Responses at 18 Months in Relapsed/Refractory Multiple Myeloma

June 8th 2021

Ciltacabtagene autoleucel, an investigational BCMA-directed CAR-T therapy, sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.

KCd Consolidation Noninferior to ASCT in Transplant-Eligible, Newly Diagnosed Multiple Myeloma

June 8th 2021

Carfilzomib consolidation with cyclophosphamide and dexamethasone conferred noninferior results compared to upfront autologous stem cell transplantation in newly diagnosed, transplant-eligible patients with multiple myeloma.

FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma

June 7th 2021

Dr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.